Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
Aligos Therapeutics, Inc. (ALGS) will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024 in Miami, Florida. The company focuses on developing therapeutics for liver and viral diseases.
02/26/2024 - 08:00 AM
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024 being held in Miami, Florida on March 11-13, 2024.
Please contact your Leerink Partners representative to schedule a one-on-one meeting.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as chronic hepatitis B (CHB) and coronaviruses.
Company jtarazi@Aligos.com
Media veames@lifescicomms.com
When will Aligos Therapeutics participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024?
Aligos Therapeutics will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference 2024 on March 11-13, 2024.
What is the focus of Aligos Therapeutics, Inc. (ALGS)?
Aligos Therapeutics, Inc. (ALGS) focuses on developing novel therapeutics to address unmet medical needs in liver and viral diseases.
Where is the Leerink Partners Global Biopharma Conference 2024 taking place?
The Leerink Partners Global Biopharma Conference 2024 is being held in Miami, Florida.
How can one schedule a one-on-one meeting with Aligos Therapeutics?
To schedule a one-on-one meeting with Aligos Therapeutics, contact your Leerink Partners representative.
ALGS Rankings
#4378 Ranked by Stock Gains
ALGS Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major
About ALGS
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.
